Skip to main content
. 2019 Sep-Oct;12(5):429–436. doi: 10.5005/jp-journals-10005-1658

Table 1.

Patient's characteristics

Prolongation of the EMONO use
N 76
Sex (M) 28/76 (37%)
Age (average) 6.6
First time EMONO 40/76 (53%)
VAS score average 7.87
Exchange 10/49 (20%)
Side effect 9/74 (12%)
Systemic pathology 17/73 (23%)
Handicap 15/73 (20%)
Medication 14/73 (19%)